Paul Peter Tak
Known title: Chief Executive OfficerCIK: 0001873905
Paul Peter Tak's purchase track record
Paul Peter Tak has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/8/2022 | CADL | $30K | -7.9% | -16.3% | +8.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CADL | ▼ Sell | Open Market | 59,379 | $621K | 9/11/2026 | View on chart |
| CADL | ▲ Buy | Option Exercise | 125,000 | $194K | 9/10/2026 | View on chart |
| CADL | ▼ Sell | Open Market | 220,866 | $2.5M | 9/10/2026 | View on chart |
| CADL | ▲ Buy | Grant | 42,826 | $200K | 6/25/2025 | View on chart |
| CADL | ▼ Sell | Open Market | 400 | $4K | 3/19/2025 | View on chart |
| CADL | ▼ Sell | Open Market | 25,772 | $226K | 3/18/2025 | View on chart |
| CADL | ▼ Sell | Open Market | 21,704 | $157K | 1/15/2025 | View on chart |
| CADL | ▼ Sell | Open Market | 21,172 | $174K | 1/8/2025 | View on chart |
| CADL | ▼ Sell | Open Market | 48,847 | $223K | 11/29/2024 | View on chart |
| CADL | ▲ Buy | Option Exercise | 12,900 | $20K | 11/21/2024 | View on chart |
| CADL | ▼ Sell | Open Market | 22,528 | $146K | 7/17/2024 | View on chart |
| CADL | ▼ Sell | Open Market | 20,293 | $121K | 7/11/2024 | View on chart |
| CADL | ▼ Sell | Tax Withholding | 43,443 | $39K | 11/28/2023 | View on chart |
| CADL | ▲ Buy | Grant | 180,108 | $0 | 11/26/2023 | View on chart |
| CADL | ▲ Buy | Open Market | 12,935 | $25K | 12/9/2022 | View on chart |
| CADL | ▲ Buy | Open Market | 3,050 | $5K | 12/8/2022 | View on chart |
| CADL | ▲ Buy | Grant | 195,906 | $0 | 11/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Candel Therapeutics Issues Inducement Grants to New Employees
Candel Therapeutics disclosed standard inducement grants awarded to newly hired employees. Under Nasdaq rules, such grants require public disclosure when given as incentives to attract talent. This is routine corporate governance news with no material impact on the company's operations or financial position. The grants align with standard market practices for biotechnology firms building their teams.
Candel Therapeutics Issues Inducement Grants to New Employees. Candel Therapeutics disclosed standard inducement grants awarded to newly hired employees. Under Nasdaq rules, such grants require public disclosure when given as incentives to attract talent. This is routine corporate governance news with no material impact on the company's operations or financial position. The grants align with standard market practices for biotechnology firms building their teams.